Thursday, June 15, 2023 | |||||||||||||||||
08:00-09:30 | REGISTRATION | ||||||||||||||||
09:30-10:15 |
WELCOME & OPENING REMARKS
|
||||||||||||||||
10:15-12:15 |
KEYNOTE SESSION 1: The vision
of the Biotechnology & Life Sciences sector: Opportunities & challenges
Chairperson: TBA Panelists:
More Speakers to be confirmed |
||||||||||||||||
12:15-14:15 | NETWORKING LUNCH - EXHIBITION BOOTH PRESENTATIONS - B2B MEETINGS | ||||||||||||||||
14:15-17:00 |
KEYNOTE SESSION 2: Bridging the Gap from Research to
Commercialization Chairperson: Georges Kotrotsios, Technology Advisor Roumai Medical; Member, Industrial Advisory Board, Swiss Academy of Engineering Sciences, Switzerland Speakers:
|
||||||||||||||||
17:00-18:30 | NETWORKING DRINKS - EXHIBITION BOOTH PRESENTATIONS - B2B MEETINGS |
Friday, June 16, 2023 | |||||||||||||
08:30-10:00 |
GREEK BIOPHARMA
INNOVATION: Your changing world with the new EU Pharma Legislation EU pharma legislation is going to change your business. What you make, where and how you sell it, and whether your business model is even viable. The European Commission published new legislative proposals in April that will redefine the business model of biotechnology in Europe. In trying to bring medicines to more patients, the legislation proposals reduce data protection, limit exclusivity for orphan medicines and brings heavy pressure to launch in all 27 Member States within two years of EMA approval. Changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups, those seeking scale up investment, clinical trials and companies going to market, often for the first time. This session/panel, chaired by EuropaBio, presents the key impacts points for biotechnology innovation within Greece, with contributions from small and large companies and policy makers – bring your voice to the discussion for the future of your own science. Chairperson: Claire Skentelbery, Director General EuropaBio, Belgium Panelists:
|
||||||||||||
10:00-12:00 |
KEYNOTE SESSION 3: The role of clinical research in
supporting disruptive innovation Chairperson: Nassos Alevizopoulos, Senior Scientific Advisor, Pharmassist Ltd, Greece Speakers:
|
||||||||||||
12:00-14:00 | NETWORKING LUNCH - EXHIBITION BOOTH PRESENTATIONS - B2B MEETINGS | ||||||||||||
14:00-16.30 |
KEYNOTE SESSION 4: Investment
Opportunities for Disruptive Innovation Round table discussions involving major EU investment stakeholders (VCs, Angel Investors, Financial Institutes) Chairperson: Elias Papatheodorou, Board Chair, HepaRegeniX (Germany) & Memo Therapeutics (Switzerland); Board member, Tribune Therapeutics, Sweden Speakers:
|
||||||||||||
16:30-18:30 | EXHIBITION BOOTH PRESENTATIONS & B2B MEETINGS |
Saturday, June 17, 2023 | |
09:30-11:30 |
Personalized Medicine - Innovative
approaches to Tailoring Disease Prevention and Treatment Chairperson: Stamatiki Kritas, Business Development Manager HBio
|
11:30-12:00 | MORNING TEA & NETWORKING |
12:00-14:00 | WORKSHOP FOR STARTUPS |
14:00-15:00 | NETWORKING LUNCH |
15:00-17:00 | PITCH YOUR IDEA |
17:00-18:00 | NETWORKING DRINKS - FINAL REMARKS - ANNOUNCEMENT OF WINNERS |